Dr. Dever is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3226 Downs Cove Road
Windermere, FL 34786Phone+1 407-222-8370Fax+1 407-214-5543
Summary
- Dr. Michael Dever is a researcher in Orlando, FL and is affiliated with multiple hospitals in the area, including Orlando Regional Medical Center and Health Central Hospital. He received his medical degree from University of Kentucky College of Medicine and has been in practice 35 years. He is experienced in travel and tropical medicine, clinical research, and insurance medicine.
Education & Training
TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986
Aultman Hospital/NEOMEDResidency, Anesthesiology, 1984 - 1984- TriHealth (Good Samaritan Hospital)Internship, Internal Medicine, 1982 - 1983
University of Kentucky College of MedicineClass of 1982
Certifications & Licensure
FL State Medical License 1985 - 2026
OH State Medical License 1985 - 1988- American Board of Internal Medicine Internal Medicine
- National Board of Physicians and Surgeons Internal Medicine
- American Academy of Insurance MedicineInsurance Medicine
- National Board of Physicians and SurgeonsDiplomate of Internal Medicine
Clinical Trials
- 12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
- Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease Start of enrollment: 2018 Aug 27
- A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain Start of enrollment: 2019 May 23
- Join now to see all
Publications & Presentations
PubMed
- 176 citationsSafety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.Edson D Moreira Jr, Nicholas Kitchin, Xia Xu, Samuel S Dychter, Stephen Lockhart
The New England Journal of Medicine. 2022-05-19 - 244 citationsTirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 tr...Stefano Del Prato, Steven E. Kahn, Imre Pavo, Govinda Weerakkody, Zhengyu Yang
Lancet. 2021-11-13 - 870 citationsSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.Stephen J. Thomas, Edson D. Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman
The New England Journal of Medicine. 2021-09-15
Journal Articles
- Serum Troponin I Assessments in 5- to 30-Year-OldsAfter BNT162b2 VaccinationTimothy E. Albertson . Caitlin Hansen . Smiti Bihari .Juleen Gayed . Xia Xu . J. Abraham Simo´ n-Campos . Michael E. Dever .Jose F. Cardona . Essack Mitha . Jeffrey B...., Infectious disease and therapy, 1/19/2024
Research History
- Principal Investigator2011 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
